CERENOME, INC.
StreetZero Signal 65
About CERENOME, INC.
Cerenome, Inc. (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being developed as part of this integrated approach.
LATEST FUNDINGPrivate Placement
$3.0M
Announced 2026-09-18
IN THE NEWS
- 🔗 Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
- 🔗 Cerenome Secures Up to $20 Million to Scale CNSide Diagnostics | citybiz
- 🔗 Pulse 2.0 - Cerenome Secures Up To $20 Million Financing...
- 🔗 Cerenome Launches as an Integrated CNS Oncology Company - Cerenome, Inc.
- 🔗 Health Care Solutions Stock Price, Funding, Valuation, Revenue & Financial Statements
EMPLOYEES—
FOUNDED—
HQHouston, TX, USA
Industry
Other Health Care
Tags
CNS OncologyDiagnosticsTherapeuticsAI
Investors
Key highlights
- Announced up to $20 million senior secured facility from 3i, LP with royalty repayments.
- CNSide diagnostics platform targets detection and monitoring of CNS cancers via CSF testing.
- Publicly listed on Nasdaq under CNSY.
- Integrated platform combines precision diagnostics, targeted therapeutics, and AI.
Ask StreetZero about CERENOME, INC.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account